Artelo Biosciences Inc

NASDAQ:ARTLUnited States

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

Contact Information

Headquarters

505 LOMAS SANTA FE, SUITE 160SOLANA BEACH, CA, United States 92075

Phone

858-925-7049

Fax

---

Executives

Independent Chairman of the Board

Connie Matsui

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary, Director

Gregory Gorgas

Independent Director

Douglas Blayney

Independent Director

R. Martin Emanuele

Independent Director

Steven Kelly